ConforMIS, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee. It also provides ConforMIS Hip System, a hip replacement product; and iJigs, a customized single-use patient-specific instrumentation. The company markets and sells its products to hospitals and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Singapore, Hong Kong, Malaysia, and Monaco. ConforMIS, Inc. was founded in 2004 and is headquartered in Billerica, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CFMS
CUSIPN/A
Phone781-345-9001
Debt
Debt-to-Equity Ratio0.60
Current Ratio4.77
Quick Ratio4.15
Price-To-Earnings
Trailing P/E Ratio-0.76
Forward P/E Ratio-1.07
P/E GrowthN/A
Sales & Book Value
Annual Sales$78.11 million
Price / Sales0.72
Cash FlowN/A
Price / CashN/A
Book Value$1.02 per share
Price / Book0.87
Profitability
EPS (Most Recent Fiscal Year)($1.24)
Net Income$-53,580,000.00
Net Margins-64.66%
Return on Equity-94.69%
Return on Assets-50.85%
Miscellaneous
Employees350
Outstanding Shares63,170,000
Market Cap$61.28 million
ConforMIS (NASDAQ:CFMS) Frequently Asked Questions
What is ConforMIS's stock symbol?
ConforMIS trades on the NASDAQ under the ticker symbol "CFMS."
How were ConforMIS's earnings last quarter?
ConforMIS Inc (NASDAQ:CFMS) issued its quarterly earnings data on Friday, August, 3rd. The medical instruments supplier reported ($0.24) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.21) by $0.03. The medical instruments supplier earned $19.10 million during the quarter, compared to analyst estimates of $19.52 million. ConforMIS had a negative net margin of 64.66% and a negative return on equity of 94.69%. View ConforMIS's Earnings History.
When is ConforMIS's next earnings date?
What price target have analysts set for CFMS?
6 equities research analysts have issued 1-year price targets for ConforMIS's stock. Their predictions range from $3.00 to $4.00. On average, they anticipate ConforMIS's share price to reach $3.75 in the next twelve months. This suggests a possible upside of 321.3% from the stock's current price. View Analyst Price Targets for ConforMIS.
What is the consensus analysts' recommendation for ConforMIS?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ConforMIS in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ConforMIS.
What are Wall Street analysts saying about ConforMIS stock?
Here are some recent quotes from research analysts about ConforMIS stock:
- 1. According to Zacks Investment Research, "ConforMIS, Inc. is a medical technology company which develops, manufacture and sells joint replacement implants. The Company's iFit technology platform consists of iFit Design, iFit Printing and iFit Just-in-Time Delivery. It operates primarily in the United States, Germany and the United Kingdom. The Company serves orthopedic surgeons, hospitals and other medical facilities and patients. ConforMIS, Inc. is based in Bedford, United States. " (8/6/2018)
- 2. BTIG Research analysts commented, "Ongoing OUS Headwinds While CFMS 2Q18 results were a bit below our expectations (rev. of $19.1M (+3% Y/Y,+2% xFx) vs. BTIG/Consensus of $19.3M/$19.4M respectively, product rev. increased Y/Y for the first time since 1Q17, growing 5% to $18.0M. Mgmt. is making progress on US commercialization (albeit slower than investors will prefer). OUS continues to be challenged in Germany but mgmt. noted recent OUS sales leadership hires that may open up a few countries in 2H18. Mgmt. commentary on payor acceptance of CFMS products indicates increasing positive traction amongst some payers but CFMS is still not where it wants to be on rep growth, which missed the 20% growth target slightly. On the call, mgmt. announced plans to reduce OpEx while shuffling its product pipeline around." (8/2/2018)
Are investors shorting ConforMIS?
ConforMIS saw a drop in short interest during the month of July. As of July 31st, there was short interest totalling 818,381 shares, a drop of 36.9% from the July 13th total of 1,297,263 shares. Based on an average daily trading volume, of 368,676 shares, the days-to-cover ratio is currently 2.2 days. Approximately 1.6% of the shares of the company are sold short. View ConforMIS's Current Options Chain.
Who are some of ConforMIS's key competitors?
Who are ConforMIS's key executives?
ConforMIS's management team includes the folowing people:
- Mr. Mark A. Augusti, CEO, Pres & Director (Age 52)
- Mr. Paul S. Weiner CPA, CFO & Treasurer (Age 54)
- Dr. Daniel Steines M.D., MS, Chief Technology Officer (Age 49)
- Mr. Ed Kilgallen, VP of Operations
- Ms. Patricia A. Davis J.D., Chief Legal Officer, Gen. Counsel & Corp. Sec. (Age 52)
When did ConforMIS IPO?
(CFMS) raised $135 million in an initial public offering (IPO) on Wednesday, July 1st 2015. The company issued 9,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Deutsche Bank Securities served as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.
Has ConforMIS been receiving favorable news coverage?
News coverage about CFMS stock has trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ConforMIS earned a news impact score of 0.17 on Accern's scale. They also gave headlines about the medical instruments supplier an impact score of 48.88 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. View Recent Headlines for ConforMIS.
Who are ConforMIS's major shareholders?
ConforMIS's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (4.76%), Sio Capital Management LLC (2.60%), ARK Investment Management LLC (1.83%), Millennium Management LLC (1.16%), Stonepine Capital Management LLC (0.98%) and BlackRock Inc. (0.91%). Company insiders that own ConforMIS stock include Bradley Langdale, Daniel Steines, David Cerveny, Mark A Augusti, Paul S Weiner and Philipp Lang. View Institutional Ownership Trends for ConforMIS.
Which institutional investors are selling ConforMIS stock?
CFMS stock was sold by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, BlackRock Inc., Sio Capital Management LLC and Laurion Capital Management LP. Company insiders that have sold ConforMIS company stock in the last year include Bradley Langdale, Daniel Steines, David Cerveny, Mark A Augusti, Paul S Weiner and Philipp Lang. View Insider Buying and Selling for ConforMIS.
Which institutional investors are buying ConforMIS stock?
CFMS stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, ARK Investment Management LLC, Millennium Management LLC, Paloma Partners Management Co, Paradigm Capital Management Inc. NY, LMR Partners LLP, Macquarie Group Ltd. and Spark Investment Management LLC. View Insider Buying and Selling for ConforMIS.
How do I buy shares of ConforMIS?
Shares of CFMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ConforMIS's stock price today?
One share of CFMS stock can currently be purchased for approximately $0.89.
How big of a company is ConforMIS?
ConforMIS has a market capitalization of $61.28 million and generates $78.11 million in revenue each year. The medical instruments supplier earns $-53,580,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis. ConforMIS employs 350 workers across the globe.
How can I contact ConforMIS?
ConforMIS's mailing address is 600 TECHNOLOGY PARK DRIVE, BILLERICA MA, 01821. The medical instruments supplier can be reached via phone at 781-345-9001 or via email at [email protected]
MarketBeat Community Rating for ConforMIS (NASDAQ CFMS)
MarketBeat's community ratings are surveys of what our community members think about ConforMIS and other stocks. Vote "Outperform" if you believe CFMS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CFMS will underperform the S&P 500 over the long term. You may vote once every thirty days.
